Session » Miscellaneous Rheumatic & Inflammatory Diseases Poster II

Date: Sunday, November 17, 2024

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2024

10:30AM-12:30PM: Abstract Number: 1113

2nd Analysis of IgG4-Related Disease in a Diverse Long Island Population: Utilizing Serological and Histological Markers for Assessing Treatment Response

10:30AM-12:30PM: Abstract Number: 1128

A Meta-Analysis of Statin Efficacy in Controlling Disease Activity in Psoriasis

10:30AM-12:30PM: Abstract Number: 1121

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of AMG 329, a Monoclonal Antibody, in Conventional and Plasmacytoid Dendritic Cell-Mediated Rheumatic Diseases

10:30AM-12:30PM: Abstract Number: 1138

Association Between Long-Term Exposure to Fine Particles and Its Components and the Onset of Systemic Autoimmune Rheumatic Diseases in Quebec

10:30AM-12:30PM: Abstract Number: 1122

Clinical Realities in Patients with Adult Onset Still’s Disease: Real-World Diagnosis and Management

10:30AM-12:30PM: Abstract Number: 1135

Deucravacitinib in Plaque Psoriasis: 4-Year Efficacy Results by Prior Biologic Treatment in the Phase 3 POETYK PSO-1, PSO-2, and Long-Term ExtensionTrials

10:30AM-12:30PM: Abstract Number: 1137

Deucravacitinib, an Oral,Selective,Allosteric Tyrosine Kinase 2 Inhibitor, in Patients WithModerate to Severe Scalp Psoriasis: Efficacy and Safety Results of a Phase 3b/4, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial (PSORIATYK SCALP)

10:30AM-12:30PM: Abstract Number: 1109

Differences Between Correlation and Causal Inference in Detecting Predictors of Undefined Crystal Arthropathy in Women

10:30AM-12:30PM: Abstract Number: 1136

Efficacy And Safety of Guselkumab Therapy in Patients With Moderately to Severely Active Crohn’s Disease: Results of the Galaxi 2 & 3 Phase 3 Studies

10:30AM-12:30PM: Abstract Number: 1106

Factors Associated with Relapse in Giant Cell Arteritis Treated with Tocilizumab. Multicenter Open-label Study of 407 Patients

10:30AM-12:30PM: Abstract Number: 1134

First-in-Human Evaluation of the Safety, Tolerability and Pharmacokinetics of the T Cell Receptor Signal Modulator AX-158

10:30AM-12:30PM: Abstract Number: 1132

Guselkumab and Golimumab Combination Induction Therapy in Ulcerative Colitis Results in Early Local Tissue Healing That Is Sustained Through Guselkumab Maintenance Therapy

10:30AM-12:30PM: Abstract Number: 1124

Impact of Genetic Predisposition for Type 2 Diabetes in Plasma Glucose Levels After the Administration of a High Dose of Systemic Glucocorticoids

10:30AM-12:30PM: Abstract Number: 1111

Impact of Scleroderma, Antiphospholipid Syndrome, Behçet’s Disease, and Dermatomyositis on Mortality Among Hospitalized Patients with Pulmonary Embolism

10:30AM-12:30PM: Abstract Number: 1107

Investigating Pyrexia of Unknown Origin: A Rheumatologist’s Perspective

10:30AM-12:30PM: Abstract Number: 1117

JAK Inhibitor Therapy in Refractory Uveitis Due to Immune-mediated Inflammatory Disorders. Multicenter Study and Literature Review

10:30AM-12:30PM: Abstract Number: 1120

Long-Term Echocardiographic Findings in Idiopathic Recurrent Pericarditis Patients Treated with Anakinra

10:30AM-12:30PM: Abstract Number: 1104

Long-term Follow-up of Patients with Positive Cryofibrinogen Test During the COVID-19 Era

10:30AM-12:30PM: Abstract Number: 1129

Machine Learning Algorithms to Predict Colchicine Resistance in Familial Mediterranean Fever

10:30AM-12:30PM: Abstract Number: 1110

Microvascular Abnormalities in COVID-19 Survivors and LONG COVID

10:30AM-12:30PM: Abstract Number: 1114

Nintedanib in Autoimmune Disease-related Interstitial Lung Disease: Real-life Effectiveness, Safety and Tolerance in a Spanish Multicenter Study

10:30AM-12:30PM: Abstract Number: 1125

Non-Classical Complications of Adult-Onset Still’s Disease: A Multicenter Spanish Study

10:30AM-12:30PM: Abstract Number: 1105

PDGFA and TGFB1, Key Genes to Discriminate Autoimmune Diseases-Related Interstitial Lung Disease from Idiopathic Pulmonary Fibrosis?

10:30AM-12:30PM: Abstract Number: 1112

Pleuroparenchymal Fibroelastosis Associated with Connective Tissue Diseases (PPFE-CTD)

10:30AM-12:30PM: Abstract Number: 1133

Relationship Between Nail Psoriasis Severity Index (NAPSI) and Cardiovascular Risk Assessed by Eight Cardiovascular Risk Calculators

10:30AM-12:30PM: Abstract Number: 1115

Rheumatic Disease Patients: Assessment of Hydroxychloroquine’s Effects on QTc Intervals with Weight Based Dosing (RAISE-QT) Study

10:30AM-12:30PM: Abstract Number: 1127

Risk of Ocular Inflammatory Conditions in Patients with Autoimmune Diseases: A Retrospective Study Using the National Inpatient Sample

10:30AM-12:30PM: Abstract Number: 1130

Safety of Bispecific T-cell Engager Therapy in Autoimmune Disease

10:30AM-12:30PM: Abstract Number: 1123

Serological Elevation of IgG4: Clinical Correlation and Differential Diagnosis

10:30AM-12:30PM: Abstract Number: 1108

The Needed Daily Dose of Colchicine in Patients with Familial Mediterranean Fever May Be Higher in Women, a Study on Behalf of the JIR Cohort

10:30AM-12:30PM: Abstract Number: 1126

The Outcomes of Carpal Tunnel Injections and Carpal Tunnel Surgery

10:30AM-12:30PM: Abstract Number: 1118

The Performance of Behcet’s Disease Clinical Diagnostic Criteria in a Low Prevalence Region. A Retrospective Single Center Cohort Study

10:30AM-12:30PM: Abstract Number: 1119

Treatment Outcomes of TNF-α Inhibitors in Cardiac Sarcoidosis

10:30AM-12:30PM: Abstract Number: 1116

Understanding the Prevalence, In-Hospital Mortality and Readmission Rates Amongst Pulmonary vs Cardiac Sarcoidosis Patients: Insights from a Nationwide Registry

10:30AM-12:30PM: Abstract Number: 1131

Zasocitinib (TAK-279), a Selective Oral Tyrosine Kinase 2 Inhibitor, Reduces Body Surface Area Involvement in a Phase 2b Trial in Moderate-to-Severe Plaque Psoriasis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].